<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" VersionID="2" Owner="NLM">
      <PMID Version="2">35246821</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2364-1746</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pulmonary therapy</Title>
          <ISOAbbreviation>Pulm Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A US Time and Motion Pilot Study of Nebulized COPD Therapy in an Inpatient and a Long-Term Care Setting.</ArticleTitle>
        <Pagination>
          <StartPage>225</StartPage>
          <EndPage>232</EndPage>
          <MedlinePgn>225-232</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s41030-022-00186-9</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">There is a lack of quantitative data on healthcare professionals' (HCPs) time dedicated to nebulized chronic obstructive pulmonary disease (COPD) therapy in inpatient and long-term care (LTC) settings. Using time and motion methodology, we quantified HCP time and opportunity costs (time and materials) associated with nebulized COPD therapy in inpatient and LTC settings and estimated efficiencies of changing to once-daily therapy.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A case report form was built to reflect local nebulization workflow. Primary outcomes were mean active HCP time per predefined task and mean total active HCP time associated with short-acting beta agonist (SABA) and SABA/short-acting muscarinic antagonist (SAMA) combination nebulization processes.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty observations occurred within each setting. Inpatient observations included three SABA and 17 SABA/SAMA (from 18 different patients), and LTC observations included five SABA and 15 SABA/SAMA (from eight different patients). Mean total process time was 16.12 min in the inpatient setting (95% CI 14.48-17.76) and 21.0 min in the LTC setting (95% CI 18.8-23.2), with the actual nebulization comprising over 50% of process time for both. In LTC, CIs suggest a difference by cognitive impairment status: mean 24.1 min (95% CI 21.3-26.9) if cognitively impaired versus 19.0 min (95% CI 16.1-21.8) if not. In the inpatient setting, the estimated process time/admission was 7.8 h; a once-daily nebulized drug would require only 2.3 h. In LTC, the estimated process time was 32.1 h/month; a once-daily nebulized drug would require only 13.7 h/month. Estimated nebulization cost was $243/admission for current versus $72 for once-daily dosing in inpatient, and $1177/month versus $504 in LTC.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The nebulization process for COPD patients in both inpatient and LTC settings consumes considerable HCP time. A switch from SABA or SABA/SAMA to a drug with a once-daily nebulization frequency could generate substantial time savings depending on the setting and site characteristics.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>De Cock</LastName>
            <ForeName>Erwin</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Syneos Health, Carrer Pau Claris, 196, 5º, 08037, Barcelona, Spain. erwin.decock@syneoshealth.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leung</LastName>
            <ForeName>Grace</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Theravance Biopharma US, Inc., South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maclaine</LastName>
            <ForeName>Grant</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Theravance Biopharma Ireland Limited, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>Hemal</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Value Matters, LLC, Ridgefield, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuhn</LastName>
            <ForeName>Brooks</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nichols</LastName>
            <ForeName>Bryan</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Intrafil Rx LLC, Salt Lake City, UT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pulm Ther</MedlineTA>
        <NlmUniqueID>101687144</NlmUniqueID>
        <ISSNLinking>2364-1754</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Albuterol sulfate</Keyword>
        <Keyword MajorTopicYN="N">Cost</Keyword>
        <Keyword MajorTopicYN="N">Ipratropium bromide</Keyword>
        <Keyword MajorTopicYN="N">Nebulization</Keyword>
        <Keyword MajorTopicYN="N">Process workflow</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35246821</ArticleId>
        <ArticleId IdType="pmc">PMC8896414</ArticleId>
        <ArticleId IdType="doi">10.1007/s41030-022-00186-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s41030-022-00186-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>American Lung Association. Understanding COPD Trends: morbidity and mortality. https://www.lung.org/blog/understanding-copd-trends. Accessed June 7, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Duarte AG, Tung L, Zhang W, et al.  Spirometry measurement of peak inspiratory flow identifies suboptimal use of dry powder inhalers in ambulatory patients with COPD. Chronic Obstr Pulm Dis. 2019;6(3):246–255. doi: 10.15326/jcopdf.6.3.2018.0163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15326/jcopdf.6.3.2018.0163</ArticleId>
            <ArticleId IdType="pmc">PMC6872217</ArticleId>
            <ArticleId IdType="pubmed">31189057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US Bureau of Labor Statistics. Occupational outlook handbook: respiratory therapists. https://www.bls.gov/ooh/healthcare/respiratory-therapists.htm. Accessed June 7, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>De Cock E, Leung G, Maclaine G, et al. Workflow mapping of nebulized COPD therapy in inpatient and long-term care (LTC) settings in the US: a precursor to an observational time and motion (T&amp;M) study. In: Poster presented at: Eastern Pulmonary Conference; September 12–15, 2019; Palm Beach, FL.</Citation>
        </Reference>
        <Reference>
          <Citation>US Bureau of Labor Statistics. Occupational employment and wages, May 2020. https://www.bls.gov/oes/current/oes291141.htm. Accessed June 7, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>US Bureau of Labor Statistics. Occupational employment and wages, May 2020. https://www.bls.gov/oes/current/oes291126.htm. Accessed June 7, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Xu H, Intrator O, Bowblis JR. Shortages of staff in nursing homes during the COVID-19 pandemic: what are the driving factors? J Am Med Dir Assoc. 2020;21(10):1371–1377. doi: 10.1016/j.jamda.2020.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jamda.2020.08.002</ArticleId>
            <ArticleId IdType="pmc">PMC7418696</ArticleId>
            <ArticleId IdType="pubmed">32981663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scales K. It is time to resolve the direct care workforce crisis in long-term care. Gerontologist. 2021;61(4):497–504. doi: 10.1093/geront/gnaa116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/geront/gnaa116</ArticleId>
            <ArticleId IdType="pmc">PMC7499598</ArticleId>
            <ArticleId IdType="pubmed">32853357</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
